首页> 外文期刊>Provider >10 STEPS TO STAFF STABILITY. PART TWO: MAXIMIZE STABILITY BY SUPPORTING AND ENGAGING STAFF.
【24h】

10 STEPS TO STAFF STABILITY. PART TWO: MAXIMIZE STABILITY BY SUPPORTING AND ENGAGING STAFF.

机译:稳定员工的10个步骤。第二部分:通过支持和参与人员最大化稳定性。

获取原文
获取原文并翻译 | 示例
           

摘要

Outcomes of hepatocellular carcinoma (HCC) lesions >3.0 cm in size including Barcelona Clinic Liver Cancer (BCLC) stage B after radiofrequency ablation (RFA) with a single electrode remain unsatisfactory. This study aimed to investigate the outcomes of RFA with multiple electrodes (ME-RFA) for HCC tumors 3.1-7.0 cm in size and BCLC stage B. This retrospective study included 70 consecutive patients with 58 medium- (3.1-5.0 cm) and 17 large- (5.1-7.0 cm) sized HCCs after ME-RFA using a controller. Outcomes in terms of complete response, primary technique effectiveness, local tumor progression, and overall survival were investigated. After 1-4 applications of ME-RFA, the rates of complete response and PTE in medium-sized tumors were 79.3% and 91.4%, respectively, and in large tumors were 76.5% and 94.1%, respectively. Overall, the major complication rate was 5.7%. After a median 21-month follow-up period, both two- and three-year estimated overall survival rates were above 80%. There were no significant differences in overall survival and local tumor progression rates between medium- and large-size tumors and among BCLC stages A, B1 and B2. A complete response to ME-RFA was the only significant factor associated with improved survival (p=0.008). In conclusion, ME-RFA can effectively treat 3.1-7.0-cm sized HCCs with a comparable outcome between medium- and large-size tumors and among BCLA stages A to B2.
机译:使用单个电极进行射频消融(RFA)后,包括巴塞罗那临床肝癌(BCLC)B期在内的大于3.0 cm的肝细胞癌(HCC)病变的结果仍然不能令人满意。这项研究的目的是研究多电极RFA(ME-RFA)治疗HCC肿瘤3.1-7.0 cm大小和BCLC B期的结果。这项回顾性研究包括70例连续的患者,其中58例中等(3.1-5.0厘米)和17例使用控制器在ME-RFA之后放置大(5.1-7.0厘米)大小的HCC。研究了在完全缓解,主要技术有效性,局部肿瘤进展和总生存率方面的结果。 1-4次应用ME-RFA后,中型肿瘤的完全缓解率和PTE分别为79.3%和91.4%,大肿瘤的完全缓解率和PTE分别为76.5%和94.1%。总体而言,主要并发症发生率为5.7%。经过21个月的中位随访期后,两年和三年的总体生存率均超过80%。在中型和大型肿瘤之间以及BCLC A,B1和B2期之间,总生存率和局部肿瘤进展率无显着差异。对ME-RFA的完全反应是与生存率改善相关的唯一重要因素(p = 0.008)。总之,ME-RFA可以有效治疗3.1-7.0厘米大小的HCC,其结果在中型和大型肿瘤之间以及BCLA A至B2期之间具有可比性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号